n-(n-(3-5-difluorophenacetyl)alanyl)phenylglycine-tert-butyl-ester and Leukemia--Erythroblastic--Acute

Notch signaling regulates the fate of hematopoietic stem cells and leukemia cells. However, the role of Notch in erythroid differentiation remains unclear.. We examined the effects of three γ-secretase inhibitors (GSI-IX, GSI-XII and GSI-XXI) that inhibit Notch signaling on the in vitro growth and differentiation of HEL and AA erythroid leukemia cell lines.. GSI treatment induced morphologic erythroid differentiation and promoted hemoglobin production. GSI treatment suppressed short-term growth and colony formation, while treatment with GSI-XXI promoted the growth of AA cells. The degree of differentiation induced by each GSI roughly correlated with the reduction in HES1 mRNA expression.. GSIs have potential uses in differentiation induction therapy for erythroid leukemia in the future. Before clinical use, in vitro sensitivity tests should be performed because the effects of GSIs are diverse depending upon the combination of leukemia cells and GSIs.

Topics: Aged; Amyloid Precursor Protein Secretases; Basic Helix-Loop-Helix Transcription Factors; Cell Differentiation; Cell Growth Processes; Cell Line, Tumor; Dipeptides; Erythroid Cells; Gene Expression; Homeodomain Proteins; Humans; Leukemia, Erythroblastic, Acute; Male; Neoplastic Stem Cells; Protease Inhibitors; Transcription Factor HES-1